EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Gossamer Bio's enterprise value is $121.66 Mil.
Gossamer Bio's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00 Mil. Therefore, Gossamer Bio's EV-to-Revenue for today is .
The historical rank and industry rank for Gossamer Bio's EV-to-Revenue or its related term are showing as below:
GOSS's EV-to-Revenue is not ranked *
in the Biotechnology industry.
Industry Median: 8.155 * Ranked among companies with meaningful EV-to-Revenue only.
As of today (2024-05-20), Gossamer Bio's stock price is $0.6833.
Gossamer Bio's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00. Therefore, Gossamer Bio's PS Ratio for today is .
Gossamer Bio EV-to-Revenue Historical Data
The historical data trend for Gossamer Bio's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Gossamer Bio's EV-to-Revenue
For the Biotechnology subindustry, Gossamer Bio's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gossamer Bio's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Gossamer Bio's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Gossamer Bio's EV-to-Revenue falls into.
Gossamer Bio's current Enterprise Value is $121.66 Mil.
Gossamer Bio's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gossamer Bio's share price for today is $0.6833.
Gossamer Bio's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gossamer Bio EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Gossamer Bio's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
GOSS has been successfully added to your 